Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
22 hedge funds and large institutions have $24.8M invested in Achilles Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 10 closing their positions.
37% more capital invested
Capital invested by funds: $18.1M → $24.8M (+$6.74M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
19% less funds holding
Funds holding: 27 → 22 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.78M |
| 2 |
CCM
Corsair Capital Management
New York
|
+$16K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.96K |
| 4 |
Morgan Stanley
New York
|
+$6.01K |
| 5 |
AIM
Arcadia Investment Management
Kalamazoo,
Michigan
|
+$2.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$904K |
| 2 |
AG
Artal Group
Luxembourg
|
-$616K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$53.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$50K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$42.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$50K | -61,391 | Closed |
|
|
XT
27
XTX Topco
George Town,
Cayman Islands
| – | -$42.1K | -51,660 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$19K | -22,813 | Closed |
|
|
HF
29
HRT Financial
New York
| – | -$8K | -10,942 | Closed |
|
|
GRP
30
Global Retirement Partners
San Rafael,
California
| – | -$1.63K | -2,000 | Closed |
|
31
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$59 | -73 | Closed |
|
ACHL Hedge Fund Activity: Q3 2024 in Review
22 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q3 2024, worth a combined $24.8M — up 37% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ACHL and 5 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was BML Capital Management, adding an estimated $2.78M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $904K sold.
- 22 institutional investors held Achilles Therapeutics (ACHL) as of Q3 2024, down from 27 in Q2 2024.
- Funds reported $24.8M of Achilles Therapeutics stock for Q3 2024, up 37% quarter-over-quarter.
- 5 funds opened new Achilles Therapeutics positions in Q3 2024 and 10 closed out, a net change of -5 holders.
- The largest Achilles Therapeutics buyer in Q3 2024 was BML Capital Management, an estimated $2.78M added.
- The largest Achilles Therapeutics seller in Q3 2024 was Baker Bros. Advisors, an estimated $904K sold.
Based on aggregated 13F filings for Q3 2024.